The facility

The Boten facility

The facility is under fit-out in the Boten Economic Zone, planned around formulation and filling on one side and protein purification on the other.

Two production modules15M units designed capacity
The Luang Pharma production halls at ground level, with the site still being worked

Photographs supplied by the company. Other images on this site are reference visuals and are captioned as such.

Where the work has reached

The photographs on this page were taken at the site in 2026. The production halls and the utilities block are up and clad, the aprons and loading bays are poured, and the surrounding earthworks are still open. What remains is the part that decides whether the facility can be licensed: the cleanroom fit-out, the equipment, the validation and the documentation.

The Boten Economic Zone's own channel has filmed the site and named Luang Pharma among the enterprises established there. In July 2026 the Boten Special Economic Zone publicly announced the project's signing into the Haichuan Industrial Park, projecting an annual output value of up to USD 30 million at full production.

Scope

Luang Pharma is establishing a pharmaceutical manufacturing facility in the Boten Economic Zone, Lao PDR. The company is not yet manufacturing, holds no manufacturing licence, and none of its portfolio lines are registered or available for supply.

The leased footprint is being prepared. The twelve-month programme covers workshop design and construction, equipment procurement and installation, connection of water, electricity and gas, HVAC and purification validation, the GMP documentation baseline, personnel training, trial production and product testing, and the manufacturing licence application.

Formulation and filling

The first module is planned for lyophilised vial products, dual-chamber cartridges, single-chamber lyophilised cartridges, 10 mL oil-based vial injections and 1 mL ampoules. Designed annual capacity for finished units is approximately 15 million.

Protein purification

The second module covers protein raw material production and purification, with a designed annual output of 80 to 100 kilograms of lyophilised protein powder.

Equipment

Twenty-nine per cent of the USD 5.0 million investment is allocated to production equipment: lyophilisers, filling machines, purification systems and analytical instruments. A further 15% covers cleanroom construction and the utility retrofit, and 12% the first-year rent and deposit on the leased area.

The site

Construction progress

The Luang Pharma buildings from the air, with the utilities block behind
The halls and the utilities block
The Luang Pharma site photographed from directly above
The site from above
The Luang Pharma site and the surrounding earthworks
The site and its earthworks
Loading bays along the front of a Luang Pharma production hall
Loading bays
The Luang Pharma buildings against the hills of the Boten zone
The buildings against the hills
A wider view of the Luang Pharma site within the economic zone
The site within the zone
The Luang Pharma halls with construction plant still on site
Plant still on site
A closer view of the Luang Pharma production buildings
The production buildings

Photographs supplied by the company. Other images on this site are reference visuals and are captioned as such.

Detail

Capital allocation

CategoryBudget (USD)Share
Production equipment1,450,00029%
Raw materials and excipients1,450,00029%
Workshop renovation750,00015%
Factory lease600,00012%
Licensing, training, logistics, contingency600,00012%
Packaging materials150,0003%
Total5,000,000100%

Contact

Write to info@luangpharma.com.